A new study illustrated that early azelastine nasal spray therapy might lower the SARS-CoV-2 load among virus-infected patients. Skip to content. Menu. Medical Home Life Sciences Home.

Hsu S, Stevens D, Sajjad F, Salapatek A. Onset of action of azelastine HCl nasal spray 0.15% evaluated in an environmental exposure chamber. Ann Allergy Asthma Immunol . 2022;125(5):S71. doi:10. ...

Azelastine nasal spray was previously approved for twice-daily use at a dose of 2 sprays per nostril in this population, and at a dose of 1 spray per nostril in patients aged 5 to 11 years with ...

Bayer announced today that the U.S. Food and Drug Administration (FDA) has approved Astepro® Allergy (Azelastine HCI .15%) as an over-the-counter (OTC ...

Girl blowing nose, allergic rhinitis, nasal congestion The FDA has approved a prescription to over-the-counter (OTC) switch for Astepro® Allergy (azelastine hydrochloride nasal spray, 0.15%).

Fluticasone propionate nasal spray reduced the symptoms of chronic sinusitis and local inflammation of the nasal cavity and adjacent sinus cavities, according to topline study results from ...

Too many of us don't know how to use nasal spray correctly, and it can hurt our sinuses in the long run. Too many of us don't know how to use nasal spray correctly, and it can hurt our sinuses in ...

The US Food and Drug Administration (FDA) has approved one formulation of azelastine (Astepro) nasal spray for nonprescription treatment of allergies, making it the first nasal antihistamine ...

The FDA has approved fluticasone propionate nasal spray for the treatment of chronic rhinosinusitis without nasal polyps in patients aged 18 years and older, according to an Optinose press release.

The FDA approved Astepro (azelastine hydrochloride nasal spray, 0.15%) for seasonal and perennial allergic rhinitis—commonly known as allergies—for adults and children six years of age and older.